Karnataka High Court Stays Pharmaceutical Licence Cancellations Pending October Hearing
The Karnataka High Court has temporarily halted the Food Safety and Drug Administration's orders cancelling and suspending pharmaceutical licences, finding that the regulatory body failed to follow mandatory procedural requirements before taking such drastic action. Justice C.M. Poonacha issued the stay on September 18 orders affecting Fortune Medical Solutions, whose licence was cancelled, and Vivanta Pharmaceuticals, whose licence was suspended, both in connection with alleged sales of spurious products.
The court's intervention centres on a critical procedural safeguard embedded in Rule 66 of the Drugs and Cosmetics Rules, 1945, which mandates that licence holders must be given an opportunity to be heard and to explain their position before any cancellation or suspension takes effect. The FSDA had acted without providing this hearing, prompting the pharmaceutical companies to approach the High Court for relief.
Justice Poonacha permitted both petitioners to continue their pharmaceutical distribution operations until the next hearing, scheduled for October 9. The court also issued notice to the FSDA and other respondents, directing them to file written replies to the petitions. This interim relief preserves the status quo and allows the affected businesses to maintain operations while the substantive issues are examined.
Sixteen Companies Consolidated for October Hearing
The scope of the court's intervention extends beyond the two named companies. On September 18, the FSDA had cancelled licences of 16 retail and wholesale pharmaceutical firms and suspended eight others, including a Pfizer depot, for alleged violations of the Drugs and Cosmetics Rules, 1945. Additional Government Advocate Rahul Cariappa informed the court that all 16 petitions from similarly placed pharmaceutical companies would be consolidated and heard together on October 9, ensuring consistent treatment of cases raising identical legal questions.
This consolidation reflects the court's recognition that a common procedural defect runs through all the FSDA orders. Each company faces the same fundamental issue: the regulator took action without providing the hearing mandated by Rule 66 before licence cancellation or suspension. By hearing the cases together, the court can establish a uniform standard for how the FSDA must proceed in such matters going forward.
Background to the FSDA Action
The FSDA's enforcement action followed raids conducted on August 18 in Bengaluru South district. During those raids, suspected counterfeit medicines worth approximately Rs 5 crore were seized. The discovery of spurious pharmaceutical products triggered the regulatory response, with the FSDA moving swiftly to cancel and suspend licences of the companies involved in the distribution chain.
While the seriousness of the alleged offences—the sale of spurious drugs—cannot be understated, the court's concern was procedural rather than substantive. The question before Justice Poonacha was not whether the FSDA had legitimate grounds to suspect wrongdoing, but whether it had followed the correct legal process before taking irreversible action against licence holders.
The Procedural Requirement at Issue
Rule 66 of the Drugs and Cosmetics Rules, 1945 is not merely a formality. It embodies the principle that even regulatory action taken in the public interest must respect the rights of the affected parties to respond to allegations against them. A licence to distribute pharmaceutical products is a valuable right, and its cancellation can cause substantial financial and reputational harm to a business.
The rule requires that before such cancellation or suspension, the licence holder must receive notice of the allegations and must be afforded a genuine opportunity to present their case. This might involve submitting written explanations, producing documents, or even appearing before the regulator to contest the charges. Without this procedural step, even a well-founded regulatory decision becomes vulnerable to legal challenge on grounds of natural justice and due process.
The FSDA's failure to observe this requirement gave the petitioners a strong basis for seeking interim relief. The court was satisfied that there was at least a prima facie case that the orders were passed in violation of Rule 66, and that the balance of convenience favoured granting a stay pending full hearing.
Implications for Pharmaceutical Regulation
The stay order does not determine whether the FSDA's underlying suspicions about spurious drugs are correct. Rather, it signals that the regulator must follow proper procedure even when acting on serious concerns. The court's decision reflects the importance of maintaining the distinction between the authority to regulate and the requirement to do so fairly.
For the FSDA, the order means that it must now prepare a detailed response to the petitioners' contentions and be ready to justify its actions at the October 9 hearing. The regulator will need to explain why it believed the circumstances warranted immediate action without prior hearing, or alternatively, it may need to conduct the hearing that Rule 66 requires before the licences can be finally cancelled or suspended.
For the pharmaceutical companies, the stay provides breathing room. They can continue operations, maintain their workforce, and fulfil their supply chain obligations while the legal process unfolds. However, the stay is temporary and conditional on the companies' compliance with any directions the court may issue and their appearance at the October 9 hearing.
The October 9 Hearing
The court has set a clear deadline for the next stage of proceedings. On October 9, Justice Poonacha will hear arguments from both the petitioners and the FSDA. At that hearing, the court will examine whether Rule 66 was properly followed, whether the FSDA had reasonable grounds to suspect the sale of spurious drugs, and what the appropriate remedy should be.
The petitioners will argue that the FSDA acted in haste and without affording them the hearing required by law. They will likely contend that they had no opportunity to explain the circumstances or to contest the allegations. The FSDA, for its part, will need to justify why it believed that immediate action was necessary and whether the procedural requirements of Rule 66 were satisfied in any form.
The court's decision on October 9 will have implications for how the FSDA conducts enforcement in the future. If the court finds that the regulator routinely bypasses the procedural safeguards in Rule 66, it may issue directions to ensure compliance. Conversely, if the FSDA can demonstrate that it had valid reasons for expedited action, the court may uphold the cancellations and suspensions, albeit potentially with modifications.
Counterfeit Medicines and Regulatory Authority
The case occurs against a backdrop of serious concerns about counterfeit medicines in India. The seizure of Rs 5 crore worth of spurious drugs reflects the scale of the problem and the real public health risks posed by unscrupulous operators in the pharmaceutical supply chain. The FSDA's enforcement efforts are a necessary response to such threats.
However, the rule of law requires that even necessary enforcement be conducted within legal bounds. The drugs and cosmetics act 1940 and rules 1945 provide the FSDA with substantial powers to protect public health, but those powers must be exercised in accordance with the procedural requirements laid down by the statute and rules. The High Court's role is to ensure that this balance is maintained.
The stay granted by Justice Poonacha does not undermine the FSDA's regulatory authority. Rather, it channels that authority in a direction that respects legal procedure. Once the FSDA conducts the hearing mandated by Rule 66, it may well reach the same conclusions about the companies' involvement in the distribution of spurious drugs and may proceed to cancel or suspend their licences on a legally sound basis.
The sixteen pharmaceutical companies and their legal teams will now prepare their submissions for the October 9 hearing. The FSDA will assemble its evidence and arguments. The court will then decide whether the regulator's actions can stand or whether they must be set aside and reconsidered with proper procedure. Until then, the affected businesses are permitted to continue operations, and the status quo is preserved.
Comments
Sign in to read the discussion and share your thoughts.